Robert A Lenz

US Patent:

20230020514, Jan 19, 2023

Filed:

Sep 2, 2022

Appl. No.:

17/902168

Inventors:

- Thousand Oaks CA, US
Eduardo DUNAYEVICH - San Diego CA, US
Robert A. LENZ - Westlake Village CA, US
Gabriel VARGAS - Berkeley CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

US Patent:

20190256607, Aug 22, 2019

Filed:

Feb 27, 2019

Appl. No.:

16/287533

Inventors:

- Thousand Oaks CA, US
Eduardo Dunayevich - San Diego CA, US
Robert A. Lenz - Westlake Village CA, US
Gabriel Vargas - Berkeley CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

US Patent:

20160311913, Oct 27, 2016

Filed:

Apr 22, 2016

Appl. No.:

15/136736

Inventors:

- Thousand Oaks CA, US
Eduardo DUNAYEVICH - San Diego CA, US
Robert A. LENZ - Westlake Village CA, US
Gabriel VARGAS - Berkeley CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.